The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”

A new method developed at Vanderbilt may help “inventory” all tumor-promoting genes.

A genetic mutation that promotes cancer development blocks the normal sorting of a protein called “Argonaute 2.”

Investigators at Vanderbilt University Medical Center have published research regarding an important feature of colorectal cancer (CRC) that could eventually lead to the development of non-invasive means of monitoring cancer progression. After lung cancer, CRC is the second-most lethal cancer in the United States.

Studies of the molecular complex that helps build specialized cellular surfaces could shed light on the mechanisms underlying a genetic deaf-blindness syndrome accompanied by intestinal disease.

A family of proteins with critical roles in cell division, synaptic transmission and cell migration don’t all function the way scientists thought they did, according to two new studies led by Vanderbilt researchers.

Vanderbilt researchers have developed a new method to study cell signaling networks at single-cell resolution.